Helpdesk

Sales contact

Home > Resources > Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Last updated: July 3, 2024

Responsiveness, reliability, professionalism, friendliness… discover why 95.6% of Kayentis clients recommend Kayentis in 2023!

Challenge your eCOA & DCT provider: choose Kayentis for your next clinical trial!

Subscribe to our newsletter

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

Better Raters,Smarter eCOA,Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events